Call the commercial booth at site #737
SOLANA BEACH, Calif., May 16, 2024 (Globe Newswire) — Evoke Pharma Co., Ltd. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the treatment of gastrointestinal (GI) diseases, with emphasis on GIMOTI.® (Metoclopramide) Nasal Spray Demonstrates Enhancement of Gastroparesis Care for Women Who Use Nasal Metoclopramide, a summary of which will be presented at 2024 Digestive Disease Week in Washington, DC, May 18-21, 2024 announced that it will be presented at the conference (DDW 2024).
“Being patient-centric is core to our mission as a company. At DDW 2024, our poster presentation will highlight GIMOTI's further benefits of improving healthcare experiences and patient outcomes. We are particularly excited about the positive treatment effects for women.This event shows that treatment with Zimoti reduces medical examinations, hospitalizations, and emergency department visits for women suffering from diabetic gastroparesis compared to oral metoclopramide. It also gives us an opportunity to further introduce our products,” said Matt D'Onofrio, CEO of Evoque Pharma.
Details of the poster presentation are as follows.
Summary title: Transforming the treatment of diabetic gastroparesis in women: Insights from the nasal use of metoclopramide
Presenter and first author: David C. Kunkel, MD, gastroenterologist and associate professor of medicine at San Diego Health University
Presentation session: Gastroparesis and small intestinal motility disorder
Poster number: 1663
Date Time: Monday, May 20th, 12:30pm – 1:30pm ET
Abstracts will be available on the DDW ePosters site and to conference attendees in the DDW Meeting Planner and mobile app beginning at 12:01 a.m. on Sunday, May 19, 2024.
Check out Evoke Pharma at DDW 2024:
For more information about GIMOTI or poster presentations, please visit Evoke. Booth number 737.
About Digestive Disease Week® (DDW)
Digestive Diet Week® (DDW) is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. DDW was co-sponsored by the American Association for Liver Diseases (AASLD), the American College of Gastroenterology (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Gastrointestinal Surgery (SSAT). – In-person and online conferences will be held from May 18th to 21st, 2024. The conference will feature more than 4,400 of his abstracts and hundreds of talks on the latest advances in gastrointestinal research, medicine, and technology. For more information, please visit www.ddw.org.
about Jimoti® (Metoclopramide) nose injection
GIMOTI is indicated to relieve symptoms in adults with acute and recurrent diabetic gastroparesis.Important safety information
Warning: Tardive Dyskinesia
-
Metoclopramide can cause tardive dyskinesia (TD), a severe and often irreversible movement disorder. The risk of developing TD increases with treatment duration and total cumulative dose.
-
Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may reduce or resolve after discontinuing metoclopramide.
-
Avoid treatment with metoclopramide (all dosage forms and routes of administration) for more than 12 weeks, as long-term use increases the risk of developing TD..
GIMOTI is not recommended for the following uses:
-
Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms, and the risk of neonatal methemoglobinemia..
-
– Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance <60 mL/min), and strong CYP2D6 inhibition due to increased drug exposure and risk of side effects patients who are using drugs concurrently.
GIMOTI is contraindicated:
-
Patients with a history of tardive dyskinesia (TD) or dystonic reaction to metoclopramide.
-
If stimulation of gastrointestinal motility is dangerous (eg, if there is gastrointestinal bleeding, mechanical obstruction, or perforation).
-
Patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause hypertension/pheochromocytoma development, possibly due to release of catecholamines from the tumor.
-
For patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.
-
Patients with hypersensitivity to metoclopramide. Reactions include angioedema and bronchospasm of the larynx and tongue.
Possible side effects associated with metoclopramide include tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), and depression. , suicidal thoughts and suicide, high blood pressure, fluid retention, hyperprolactinemia, and health effects. Ability to drive and operate machinery. The most common side effects (greater than 5%) of GIMOTI are taste disturbance, headache, and fatigue. These are not all possible side effects of GIMOTI. Seek medical advice from your doctor about whether you should take GIMOTI, possible risk factors and side effects. We encourage you to report negative side effects of your prescription medications to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
about evoke Pharmaceutical company, Co., Ltd.
Evoke is a specialty pharmaceutical company primarily focused on the development of drugs to treat gastrointestinal diseases and diseases. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a gastrointestinal disease that affects millions of people worldwide, in which the stomach takes too long to empty, resulting in severe gastrointestinal symptoms and other symptoms. causes systemic complications. Gastric lag caused by gastroparesis can impair the absorption of orally administered drugs. Before the FDA approved his GIMOTI for commercial sale, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States for the treatment of gastroparesis. .
safety port statement
Evoke cautions you that statements contained in this press release that are not statements of historical fact are forward-looking statements. In some cases, the words “may”, “will”, “should”, “expected”, “plans”, “anticipated”, “could”, ” You can identify forward-looking statements by terms such as “intends” and “targets”. “anticipate,” “contemplate,” “believe,” “estimate,” “predict,” “may,” “continue” or the negative of these terms, or other similar expressions; . These statements are based on our current beliefs and expectations. These forward-looking statements include statements regarding: 2024 Net Product Sales Guidance. potential future prescribing trends for GIMOTI based on Evoke or EVERSANA marketing efforts; Evoke's commercialization plans, including the potential for GIMOTI to become a standard treatment for gastroparesis; the potential for additional financing from the exercise of outstanding warrants and Evoke's anticipated financing options; The inclusion of forward-looking statements should not be considered a representation by Evoke that any of its plans will be achieved. Actual results may differ from those described in this press release due to risks and uncertainties inherent in Evoke's business. Including but not limited to: Evoke may not be able to achieve its 2024 guidance, including as a result of reduced demand for GIMOTI. Evoke and EVERSANA can successfully drive market demand for GIMOTI. Evoke may raise additional funding as needed to support its operations. Evoke may exhaust its capital resources sooner than expected. Holders of stock acquisition rights may choose not to exercise their outstanding stock acquisition rights. Evoke relies on third parties for the manufacture of his GIMOTI. Evoke is completely dependent on the success of his GIMOTI. unsatisfactory efficacy or unexpected adverse side effects related to GIMOTI, which could result in recalls or product liability claims; Evoke's ability to maintain protection of GIMOTI's intellectual property; Other risks and uncertainties are described more fully in Evoke's previous press releases and periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date of this document. All forward-looking statements are qualified in their entirety by this cautionary statement. This warning is made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor and Media Contact:
Daniel Comte Boateng
DKB Partners
Phone: 862-213-1398
dboateng@dkbpartners.net